DB
SGMT icon

Dmitry Balyasny’s Sagimet Biosciences SGMT Stock Holding History

Dmitry Balyasny’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28M Buy
+3,626,113
New +$24.7M 0.03% 569
2025
Q2 		– Sell
-242,840
Closed -$792K – 3296
2025
Q1 		$792K Buy
+242,840
New +$1.02M ﹤0.01% 2096

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dmitry Balyasny's SGMT Position: Q2 2026 in Review

Dmitry Balyasny opened a new position in Sagimet Biosciences (SGMT) in Q2 2026: 3,626,113 shares worth $28M. The stake represents 0.03% of the portfolio and ranks #569 among its holdings. This is a return to the name: Dmitry Balyasny previously reported a position in SGMT as recently as Q1 2025.

Dmitry Balyasny first reported a position in SGMT in Q1 2025 and has held it in 2 quarters since. 121 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Dmitry Balyasny held 3,626,113 shares of Sagimet Biosciences worth $28M as of Q2 2026.
  • Sagimet Biosciences was a new Dmitry Balyasny position in Q2 2026.
  • Sagimet Biosciences made up 0.03% of Dmitry Balyasny's portfolio in Q2 2026, its #569 holding.
  • Dmitry Balyasny first reported a position in Sagimet Biosciences in Q1 2025 and has held it in 2 quarters since.
  • 121 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.